Viral load detection and management on first line ART in rural Rwanda.
Anti-retroviral therapy
Detectable viral load
viral load
viral suppression
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
03 Jan 2019
03 Jan 2019
Historique:
received:
22
02
2018
accepted:
19
12
2018
entrez:
5
1
2019
pubmed:
5
1
2019
medline:
12
2
2019
Statut:
epublish
Résumé
To achieve the ambitious 90-90-90 UNAIDS targets, access to routine viral load (VL) is critical. To measure VL, Rwanda has relied on a national reference laboratory for years. In 2014, a VL testing platform was implemented in a rural District in the Northern Province. Here we analyze the uptake of VL testing, identification of risks for detectable VL (≥1000 copies/ml), and the management of patients with a detectable VL. A retrospective cohort study of patients who started ART between July 2012 and June 2015 and followed until end December 2016. Using descriptive statistics, we describe the VL cascade, from VL uptake to the start of second-line ART in patients diagnosed with virological failure. We estimate predictors of having a detectable VL using logistic regression. The uptake of VL testing increased progressively between 2013 and 2016, raising from 25.6% (39/152) in 2013 up to 93.2% (510/547) in 2016.In 2016, 88.5% (n = 451) of patients tested, had a suppressed VL. Predictors of having a detectable VL included being male (aOR 2.1; 95%CI 1.12-4.02; p = 0.02), being a sex worker (aOR 6.4; 95%CI 1.1-36.0; p = 0.04), having a WHO clinical stage IV when starting ART (aOR 8.8; 95%CI 1.8-43.0; p < 0.001), having had a previous detectable VL (aOR 7.2; 95%CI 3.5-14.5; p < 0.001), and having had no VL before 2016 (aOR 3.1; 95%CI 1.2-8.1; p = 0.02). Among patients with initial detectable VL between 2013 and 2016, 88% (n = 103) had a follow-up VL, of whom 60.2% (n = 62) suppressed their VL below 1000 copies/ml. The median time between the initial and follow-up VL was of 12.5 months (IQR: 8.7-19.0). Among patients with confirmed treatment failure, 63.4% (n = 26) started second-line ART within the study period. VL uptake increased after decentralizing VL testing in rural Rwanda. Virological suppression was high. An individualized follow up of patients at risk of non-suppression and a prompt management of patients with detectable VL may help to achieve and sustain the third global UNAIDS target: virological suppression in 90% of patients on ART.
Sections du résumé
BACKGROUND
BACKGROUND
To achieve the ambitious 90-90-90 UNAIDS targets, access to routine viral load (VL) is critical. To measure VL, Rwanda has relied on a national reference laboratory for years. In 2014, a VL testing platform was implemented in a rural District in the Northern Province. Here we analyze the uptake of VL testing, identification of risks for detectable VL (≥1000 copies/ml), and the management of patients with a detectable VL.
METHODS
METHODS
A retrospective cohort study of patients who started ART between July 2012 and June 2015 and followed until end December 2016. Using descriptive statistics, we describe the VL cascade, from VL uptake to the start of second-line ART in patients diagnosed with virological failure. We estimate predictors of having a detectable VL using logistic regression.
RESULTS
RESULTS
The uptake of VL testing increased progressively between 2013 and 2016, raising from 25.6% (39/152) in 2013 up to 93.2% (510/547) in 2016.In 2016, 88.5% (n = 451) of patients tested, had a suppressed VL. Predictors of having a detectable VL included being male (aOR 2.1; 95%CI 1.12-4.02; p = 0.02), being a sex worker (aOR 6.4; 95%CI 1.1-36.0; p = 0.04), having a WHO clinical stage IV when starting ART (aOR 8.8; 95%CI 1.8-43.0; p < 0.001), having had a previous detectable VL (aOR 7.2; 95%CI 3.5-14.5; p < 0.001), and having had no VL before 2016 (aOR 3.1; 95%CI 1.2-8.1; p = 0.02). Among patients with initial detectable VL between 2013 and 2016, 88% (n = 103) had a follow-up VL, of whom 60.2% (n = 62) suppressed their VL below 1000 copies/ml. The median time between the initial and follow-up VL was of 12.5 months (IQR: 8.7-19.0). Among patients with confirmed treatment failure, 63.4% (n = 26) started second-line ART within the study period.
CONCLUSION
CONCLUSIONS
VL uptake increased after decentralizing VL testing in rural Rwanda. Virological suppression was high. An individualized follow up of patients at risk of non-suppression and a prompt management of patients with detectable VL may help to achieve and sustain the third global UNAIDS target: virological suppression in 90% of patients on ART.
Identifiants
pubmed: 30606128
doi: 10.1186/s12879-018-3639-y
pii: 10.1186/s12879-018-3639-y
pmc: PMC6318862
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
8Références
J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):370-80
pubmed: 22820803
J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):74-8
pubmed: 23774877
AIDS. 2014 Sep 10;28(14):2097-107
pubmed: 24977440
PLoS One. 2015 Feb 19;10(2):e0116144
pubmed: 25695494
BMC Med. 2015 Sep 09;13:216
pubmed: 26354601
Lancet HIV. 2015 May;2(5):e208-15
pubmed: 26423003
Lancet HIV. 2015 Jul;2(7):e271-8
pubmed: 26423252
Clin Infect Dis. 2016 Apr 15;62(8):1043-8
pubmed: 26743094
J Int AIDS Soc. 2016 Feb 15;19(1):20673
pubmed: 26894388
Lancet HIV. 2016 May;3(5):e221-30
pubmed: 27126489
PLoS One. 2016 Aug 22;11(8):e0161469
pubmed: 27548695
MMWR Morb Mortal Wkly Rep. 2016 Dec 02;65(47):1332-1335
pubmed: 27906910
PLoS One. 2016 Dec 22;11(12):e0168671
pubmed: 28006001
J Int AIDS Soc. 2017 Mar 22;20(1):21371
pubmed: 28630651
Int Health. 2017 Jul 1;9(4):206-214
pubmed: 28810670